Intellia Therapeutics, Inc.
- Jurisdiction
United States - LEI
5493002T5BCPE5DZC723 - ISIN
US45826J1051 (NTLA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Read full profile
Fundamentals
- Net revenue
€45.08M - Gross margin
95.1% - EBIT
-€436.73M - EBIT margin
-968.7% - Net income
-€409.58M - Net margin
-908.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| CHASE WILLIAM J | N/A |
|
|
|
|
| Dulac Edward J III | EVP, Chief Financial Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)